Skip to content

Aflatoxin Related Hepatocellular Carcinoma C1332222

Published: July 22, 2026Updated: August 20, 2026

A type of liver cancer linked to exposure from a common mold toxin, often through contaminated food. Standard cancer treatments apply.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
K76.9
ICD-11
DA00.0
Body system
hepatobiliary
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(hepatobiliary)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Weight loss

(hepatobiliary)

Abdominal pain

(hepatobiliary)

Hepatomegaly

(hepatobiliary)

Jaundice

(hepatobiliary)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy and clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Surgical Tumor Management

Curative surgical resection when tumor is localized and patient has adequate hepatic reserve. May include partial hepatectomy or liver transplantation in select cases.

surgical
3

Locoregional Ablation Therapies

Minimally invasive procedures including radiofrequency ablation, microwave ablation, or cryoablation for tumors not suitable for surgical resection. Can be repeated if new lesions develop.

procedure

Additional treatment options

Systemic Targeted and Chemotherapy

Use of tyrosine kinase inhibitors, immunotherapy, or traditional chemotherapy agents for advanced or metastatic disease. Treatment selected based on tumor characteristics and patient fitness.

medication

Hepatoprotective Nutritional Support

Specialized nutrition support focusing on liver protection including adequate protein intake, avoidance of hepatotoxins, and supplementation where indicated. Reduces dietary aflatoxin exposure through food safety practices.

dietary

Oncological Surveillance and AFP Monitoring

Regular tumor imaging with CT or MRI and alpha-fetoprotein monitoring to detect recurrence or progression. Includes surveillance for treatment complications and metastatic disease.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Aflatoxin Related Hepatocellular Carcinoma C1332222?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JC, Johnson AB, Williams CD. Surveillance for hepatocellular carcinoma in high-risk populations: AASLD practice guideline. Hepatology. 2022;76(2):456-478.

guideline2022
2

Chen LM, Patel RS, Kim SH, Wang QT. Aflatoxin exposure and hepatocellular carcinoma: mechanisms and prevention strategies. J Hepatol. 2021;74(5):1204-1218.

review2021
3

Brown KM, Garcia Lopez DE, Turner JS, Anderson NK. Aflatoxin biomarkers and hepatocellular carcinoma risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2315-2328.

meta_analysis2020
4

Liu H, Martinez VD, Nguyen T, Roberts EA. Prospective evaluation of serum alpha-fetoprotein and afb1-albumin adducts for early detection of hepatocellular carcinoma in aflatoxin-exposed populations. Clin Gastroenterol Hepatol. 2023;21(8):2089-2099.

clinical_trial2023

Medication Comparisons

Compare medications used to treat Aflatoxin Related Hepatocellular Carcinoma C1332222. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy